AFAMELANOTIDE

( DrugBank: Afamelanotide / KEGG DRUG: Afamelanotide )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
159	色素性乾皮症	6

告示番号	疾患名（ページ内リンク）	臨床試験数
254	ポルフィリン症	11

159. 色素性乾皮症

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

trials per page:

Showing 1 to 6 of 6 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05370235 (ClinicalTrials.gov)	March 28, 2022	21/4/2022	A Study to Evaluate the Safety and Efficacy of Afamelanotidein Patients With Xeroderma Pigmentosum C ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Xeroderma Pigmentosum	Drug: Afamelanotide	Clinuvel Europe Limited	NULL	Recruiting	18 Years	75 Years	All	6	Phase 2	Belgium;Spain
2	EUCTR2021-001419-10-ES (EUCTR)	31/01/2022	17/11/2021	Study to evaluate the safety and the efficacy of the photoprotective drug, afamelanotidein patients ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: SCENESSE Product Name: Afamelanotide (16 mg implant)	CLINUVEL EUROPE LIMITED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Belgium;Spain
3	NCT05159752 (ClinicalTrials.gov)	October 19, 2021	9/11/2021	A Study to Evaluate the Safety and Efficacy of Afamelanotidein Patients With Xeroderma Pigmentosum ( ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Xeroderma Pigmentosum	Drug: Afamelanotide	Clinuvel Europe Limited	NULL	Recruiting	18 Years	75 Years	All	6	Phase 2	Germany
4	EUCTR2021-003642-20-DE (EUCTR)	27/09/2021	09/07/2021	Study to Evaluate the Safety and Efficacy of Afamelanotidein Patients withXeroderma Pigmentosum (XP) ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous I ...	xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases ...	Trade Name: SCENESSE Product Name: SCENESSE INN or Proposed INN: Afamelanotide	CLINUVEL EUROPE LTD	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Germany
5	EUCTR2019-000597-34-DE (EUCTR)	01/06/2021	11/01/2021	Study to Evaluate the Safety and Efficacy of Afamelanotidein Patients withXeroderma Pigmentosum (XP) ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous I ...	xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases ...	Trade Name: SCENESSE Product Name: SCENESSE INN or Proposed INN: AFAMELANOTIDE	CLINUVEL EUROPE LIMITED	NULL	Not Recruiting			Female: yes Male: yes	6	Phase 2	Germany
6	EUCTR2021-001419-10-BE (EUCTR)		16/11/2021	Study to evaluate the safety and efficacy of the photoprotective drug, afamelanotidein patients with ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: SCENESSE Product Name: Afamelanotide (16 mg implant)	CLINUVEL EUROPE LIMITED	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Spain;Belgium

First Previous1Next Last

254. ポルフィリン症

臨床試験数 : 72 / 薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

trials per page:

Showing 1 to 10 of 11 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004164-60-NL (EUCTR)	19/05/2022	21/02/2022	Study to Evaluate the Safety and Efficacy of Afamelanotidein Patients with Variegate Porphyria (VP)- ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide ...	Variegate Porphyria (VP)-related skin disease;Therapeutic area: Body processes [G] - Metabolic Pheno ...	Trade Name: SCENESSE	CLINUVEL (UK) LTD	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Netherlands;Switzerland
2	NCT01605136 (ClinicalTrials.gov)	May 2012	22/5/2012	Phase III Confirmatory Study in Erythropoietic Protoporphyria	A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety a ...	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited	NULL	Completed	18 Years	N/A	All	93	Phase 3	United States
3	NCT04578496 (ClinicalTrials.gov)	July 11, 2011	5/10/2020	A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)	A Phase III, Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)	Erythropoietic Protoporphyria	Drug: Afamelanotide	Clinuvel Pharmaceuticals Limited	NULL	Completed	18 Years	75 Years	All	16	Phase 3	NULL
4	NCT01097044 (ClinicalTrials.gov)	April 2010	30/3/2010	Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)	A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety an ...	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited	NULL	Completed	18 Years	N/A	All	77	Phase 2	United States
5	EUCTR2009-011018-51-IE (EUCTR)	09/03/2010	20/01/2010	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	Erythropoietic Protoporphyria (EPP). MedDRA version: 12.1;Level: LLT;Classification code 10015289;Te ...	Product Name: afamelanotide Product Code: CUV1647 INN or Proposed INN: Afamelanotide	Clinuvel Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	Finland;United Kingdom;Netherlands;Ireland
6	NCT00979745 (ClinicalTrials.gov)	September 2009	17/9/2009	Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited	NULL	Completed	18 Years	70 Years	Both	70	Phase 3	Finland;France;Germany;Ireland;Netherlands;United Kingdom
7	EUCTR2009-011018-51-FI (EUCTR)	18/08/2009	20/04/2009	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	Erythropoietic Protoporphyria (EPP) MedDRA version: 9.1;Level: LLT;Classification code 10015289;Term ...	Product Name: afamelanotide Product Code: CUV1647	Clinuvel Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	Finland;United Kingdom;Netherlands;Ireland
8	EUCTR2009-011018-51-NL (EUCTR)	06/08/2009	03/04/2009	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety a ...	Erythropoietic Protoporphyria (EPP) MedDRA version: 9.1;Level: LLT;Classification code 10015289;Term ...	Product Name: afamelanotide Product Code: CUV1647	Clinuvel Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	Finland;United Kingdom;Netherlands;Ireland
9	EUCTR2009-011018-51-GB (EUCTR)	15/06/2009	27/04/2009	A Phase III, Safety Extension Study in Patients withErythropoietic Protoporphyria (EPP) - Phase III ...	A Phase III, Safety Extension Study in Patients withErythropoietic Protoporphyria (EPP) - Phase III ...	Erythropoietic Protoporphyria (EPP) MedDRA version: 13.1;Level: LLT;Classification code 10015289;Ter ...	Product Name: Afamelanotide Product Code: CUV1647 INN or Proposed INN: afamelanotide Other descriptive ...	Clinuvel Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	15	Phase 3	Finland;United Kingdom;Netherlands;Ireland
10	NCT04053270 (ClinicalTrials.gov)	May 2007	8/8/2019	Multicentre Phase III Erythropoietic Protoporphyria Study	A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy o ...	Erythropoietic Protoporphyria	Drug: Afamelanotide;Drug: Placebo	Clinuvel Pharmaceuticals Limited	NULL	Completed	18 Years	70 Years	All	100	Phase 3	NULL

First Previous1 2Next Last